AVXL net incomeQ3 2026$7.82M
AVXL net income was $7.82M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$13.24M a year earlier. For the full fiscal 2025 it was -$46.38M, compared with -$43.00M in fiscal 2024.
Anavex Life Sciences Corp. (AVXL) financials
For the twelve months ended Jun 30, 2026, Anavex Life Sciences Corp. reported -$13.02M of net income.
- Net income, TTM
- -$13.02M
- Cash
- $118.33M
- Market cap
- $113.1M
FY2016FY2025
AVXL revenue and earnings growth
AVXL EPSQ3 2026$0.08
AVXL diluted EPS was $0.08 in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$0.16 a year earlier. For the full fiscal 2025 it was -$0.54, compared with -$0.52 in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M | $25.23M | $22.26M | $13.34M | $10.67M | $7.25M |
| Selling, general and admin | $13.82M | $11.04M | $12.05M | $13.07M | $9.02M | $5.86M | $6.85M | $5.99M | $5.01M | $8.33M |
| Operating income | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42.00M | -$31.09M | - | - | - | - |
| Pre-tax income | -$46.38M | -$43.00M | -$47.50M | -$47.62M | -$37.64M | -$26.26M | -$26.21M | -$17.18M | -$13.40M | -$14.71M |
| Net income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M | -$26.28M | -$26.29M | -$17.25M | -$13.46M | -$14.74M |
| EPS, basic | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 |
| EPS, diluted | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 |
| Diluted shares | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M | 58.2M | 48.9M | 44.7M | 40.8M | 35.2M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $102.58M | $132.19M | $151.02M | $149.16M | $152.11M | $29.25M | $22.19M | $22.93M | $27.44M | $9.19M |
| Current assets | - | - | - | - | - | - | $25.33M | $26.05M | $27.79M | $9.45M |
| Total assets | $103.81M | $135.57M | $154.39M | $152.71M | $161.62M | $34.54M | $25.33M | $26.21M | $27.84M | $9.50M |
| Current liabilities | - | - | - | - | $10.80M | $7.31M | $5.04M | $3.88M | $3.58M | $3.19M |
| Total liabilities | $8.95M | $15.30M | $12.53M | $10.21M | $10.80M | $7.31M | $5.04M | - | $3.58M | $3.19M |
| Shareholders' equity | $94.87M | $120.26M | $141.85M | $142.49M | $150.82M | $27.24M | $20.29M | $22.32M | $25.88M | $6.31M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M | -$21.29M | -$18.53M | -$12.58M | -$9.02M | -$9.24M |
| Financing cash flow | $9.43M | $11.97M | $29.65M | $21.29M | $153.24M | $28.35M | $17.78M | $8.07M | $27.27M | $3.13M |
| Stock-based compensation | $11.55M | $9.44M | $16.37M | $18.38M | $8.23M | $4.88M | $6.43M | $5.52M | $4.14M | $5.06M |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | $1.3K |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -48.9% | -35.8% | -33.5% | -33.7% | -25.1% | -96.5% | -129.6% | -77.3% | -52.0% | -233.6% |
| Return on assets | -44.7% | -31.7% | -30.8% | -31.4% | -23.5% | -76.1% | -103.8% | -65.8% | -48.4% | -155.1% |
| Current ratio | - | - | - | - | - | - | 5.03 | 6.71 | 7.75 | 2.96 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | $4.19M | $4.66M | $7.29M | $9.96M | $9.89M | $10.45M | $11.61M | $11.81M | $9.73M | $8.68M | $10.06M |
| Selling, general and admin | $2.03M | $2.29M | $2.13M | $3.55M | $4.50M | $2.62M | $3.15M | $2.66M | $2.79M | $2.90M | $2.69M | $2.60M |
| Operating income | $6.74M | -$6.48M | -$6.78M | -$10.84M | -$14.46M | -$12.51M | -$13.59M | -$14.27M | -$14.60M | -$12.62M | -$11.38M | -$12.66M |
| Pre-tax income | - | - | - | - | - | - | - | -$11.74M | -$12.28M | -$10.44M | -$8.54M | -$10.21M |
| Income tax | $0 | $0 | $18.0K | - | - | - | - | - | - | - | - | - |
| Net income | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | -$11.20M | -$12.11M | -$11.62M | -$12.21M | -$10.55M | -$8.62M | -$10.15M |
| EPS, basic | $0.08 | -$0.06 | -$0.06 | - | -$0.16 | -$0.13 | -$0.14 | -$0.14 | -$0.14 | -$0.13 | -$0.11 | -$0.12 |
| EPS, diluted | $0.08 | -$0.06 | -$0.06 | - | -$0.16 | -$0.13 | -$0.14 | -$0.14 | -$0.14 | -$0.13 | -$0.11 | -$0.12 |
| Diluted shares | 92.90B | 92.7M | 89.0M | - | 85.38B | 85.1M | 84.8M | - | 84.5M | 82.5M | 82.1M | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $118.33M | $127.42M | $131.75M | $102.58M | $101.16M | $115.77M | $120.78M | $132.19M | $138.76M | $139.39M | $143.76M | $151.02M |
| Total assets | $120.14M | $128.77M | $132.99M | $103.81M | $102.43M | $117.14M | $124.04M | $135.57M | $141.53M | $144.52M | $148.07M | $154.39M |
| Total liabilities | $7.69M | $7.06M | $6.37M | $8.95M | $11.47M | $17.38M | $13.13M | $15.30M | $11.75M | $9.56M | $12.49M | $12.53M |
| Shareholders' equity | $112.45M | $121.71M | $126.62M | $94.87M | $90.96M | $99.76M | $110.92M | $120.26M | $129.78M | $134.96M | $135.57M | $141.85M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.10M | -$4.44M | -$7.15M | -$8.60M | -$12.46M | -$5.86M | -$12.12M | -$6.66M | -$5.18M | -$11.66M | -$7.32M | -$5.85M |
| Financing cash flow | $0 | $113.0K | $36.32M | $10.02M | -$2.14M | $852.0K | $708.0K | $89.0K | $4.55M | $7.28M | $59.0K | $2.06M |
| Stock-based compensation | -$17.08M | $314.0K | $1.11M | $3.72M | $4.32M | $1.45M | $2.06M | $2.01M | $2.49M | $2.65M | $2.29M | $3.19M |
Key ratios
Source: XBRL data Anavex Life Sciences Corp. files with the SEC, latest filing dated Aug 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-4, first reported Feb 8, 2016.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AVXL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AVXL | - | - | -$13.02M | - | $113.1M |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| PRTA | $52.73M | +347.4% | -$23.96M | -45.4% | $450.9M |
| ABOS | - | - | -$103.96M | - | $17.6M |
| ANVS | $0 | - | -$49.52M | - | $38.6M |
| CGTX | - | - | -$15.99M | - | $65.3M |
AVXL FAQ
4 questionsIs AVXL profitable?
No. Anavex Life Sciences Corp. reported a net loss of $13.02M for the twelve months ended Jun 30, 2026.How much cash and debt does AVXL have?
Anavex Life Sciences Corp. reported $118.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did AVXL last report financial results?
The latest statements here come from Anavex Life Sciences Corp.'s 10-Q filed on Aug 28, 2026, covering the period ended Jun 30, 2026.Where does this AVXL financial data come from?
Quantisnow builds these statements from the structured XBRL data Anavex Life Sciences Corp. files with the SEC. It is provided for information only and is not investment advice.